$ブライアセル・セラピューティクス(BCTX.US)$BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS(TM) IND
Pawtastic :
oh...this stock is sucking blood. i sold half at a lost. but the other half is losing more n more. is there even any hope for this? should i sell or wait? my cost is 10.50
Gainers: •$Antares Pharma(ATRS.US)$+48.7% (to be acquired by Halozyme (HALO) for $5.60 per share) •$Sierra Oncology(SRRA.US)$+37.9% (acquired by GSK for $55 per share) •$Amryt Pharma(AMYT.US)$+11.7% (announces positive long-term safety and efficacy data for Mycapssa (oral octreotide) from the 2nd Year of OPTIMAL open label extension study in acromegaly patients) •$ブライアセル・セラピューティクス(BCTX.US)$+6% (presents development details of...
ブライアセル・セラピューティクスに関するコメント
I should of never bought this morning. I wasn't awake yet and thought I was doing something good. now. I'm screwed
コラムToday's pre-market stock movers: DAL, JPM, NSTG, ATRS and more
•$Antares Pharma(ATRS.US)$ +48.7% (to be acquired by Halozyme (HALO) for $5.60 per share)
•$Sierra Oncology(SRRA.US)$ +37.9% (acquired by GSK for $55 per share)
•$Amryt Pharma(AMYT.US)$ +11.7% (announces positive long-term safety and efficacy data for Mycapssa (oral octreotide) from the 2nd Year of OPTIMAL open label extension study in acromegaly patients)
•$ブライアセル・セラピューティクス(BCTX.US)$ +6% (presents development details of...
まだコメントはありません